Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients

Exclusion Criteria

• •Pregnant and lactating women, or female patients of child-bearing age without taking contraceptive measures
• •* Patients with severe acute infection without being controlled effectively or having pyogenic and chronic infections with persistently unhealed wounds
• •* Past history of serious heart diseases, including: cardiac function classification ≥NYHA class II, unstable angina pectoris, myocardial infarction, arrhythmia requiring anti-arrhythmic drug therapy (excluding β-blockers or digoxin), and uncontrolled hypertension
• •* Patients with a history of HIV infection or active phase of chronic hepatitis B/C
• •* negative imaging examination result 4 weeks prior to enrollment)
• •* Epilepsy patients requiring drug therapy (e.g. steroids or antiepileptic drugs)
• •* A history of allogeneic organ transplantation
• •* Patients with evidence of hemorrhagic constitution or a past history of hemorrhage
• •* Patients currently receiving renal dialysis
• •* Past or present concomitant tumors with the primary lesions or histological characteristics different from the tumors evaluated in this study, excluding other tumor cured longer than 3 years before enrollment
• •* Patients participating in other clinical trials simultaneously